New research calls for a health equity lens in commercial tobacco product regulation

Innovation
Jul.19.2022

University of Minnesota School of Public Health Assistant Professor Dana Mowls Carroll co-authored a recent commentary in Preventive Medicine on how commercial tobacco policies contribute to inequities, including the unequal and unjust burden of tobacco-related disease and death among racialized populations.

The researchers explained that policies allow the continued sale of menthol cigarettes — especially via targeted marketing — that increase the risk of commercial tobacco use among Black or African American (B/AA) and Indigenous American adults. At the same time, policies banning e-cigarette flavors to prevent young people from starting to vape have received considerable attention. These policies disproportionately benefit white youth, whose  e-cigarette use is higher compared to B/AA youth. Although youth e-cigarette use prevention is critical, the level of support, urgency and publicity for banning e-cigarette flavors exceeds that for banning menthol cigarettes, furthering inequities in how regulation benefits various groups.

 

The writers assert that equitable opportunities for a healthy life can no longer be afterthoughts or secondary aims for policymakers, and call for a health equity lens in commercial tobacco product regulation and provide individual and system-level recommendations that put health equity at the forefront of regulation and research.

New research calls for a health equity lens in commercial tobacco product regulation

Their recommendations include:

The Food and Drug Administration — which regulates commercial tobacco products at the national level — should address health equity directly while evaluating regulations and prioritizing research that examines how regulations, or lack thereof, may increase or decrease commercial tobacco-related health inequities experienced by B/AA and Indigenous American groups.

Community engagement is critical and public health professionals must be prepared to do this well. This approach can be used to authentically engage with populations at greatest risk for tobacco-related disease and ensure their voices and wisdom are prioritized during policy development and implementation.

More B/AA and Indigenous American tobacco regulatory science researchers should be mentored, recruited and supported in their training.

This work must start with understanding the roots of inequities. All researchers must educate themselves about the cultural and historic contexts in which their academic and community institutions exist and their impacts on B/AA and Indigenous communities.

“Striving for the highest possible standard of health for all people means that we must educate ourselves on the true roots of inequities, particularly racism, and identify public health approaches and policies that are anti-racist,” said Carroll. “I am interested in how populations that bear the greatest smoking-related burdens benefit to a lesser extent from, or can even be harmed by, the implementation or lack of tobacco-related policies when compared with socially privileged populations.”

 

This research was supported by the National Institute on Drug Abuse of the National Institutes of Health (NIH), by the National Institute on Minority Health and Health Disparities of the NIH and the Center for Tobacco Products of the U.S. Food and Drug Administration. 

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Japan Tobacco (JT) will expand EVO Cacao Mint Crystal from limited channels to nationwide retail in Japan from October 6, 2026. The Ploom tobacco stick ranked first in the brand's first consumer voting campaign for new tobacco-stick SKUs held earlier this year. JT will also introduce a limited 22-stick pack at the same JPY 620 price as the standard 20-stick pack. The capsule-format product combines menthol with sweet, bittersweet cacao notes and adds a berry nuance when the capsule is crushed.
Sep.09
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
SMOORE’s DOJO by VAPORESSO to Launch New Global Brand Identity on September 1
According to recent LinkedIn posts from people at VAPORESSO, SMOORE and a German distribution partner, vape brand DOJO will begin rolling out a new global brand identity on September 1, 2026, led by a redesigned handwritten logo. The new visual system will be gradually applied across product packaging, marketing materials and digital assets over the following months. Fabio Corsaro, Head of Marketing and Purchasing at MG Wesel GmbH, said the rebrand was related to trademark issues, but that explanation has not been publicly confirmed by DOJO, VAPORESSO or SMOORE. DOJO is currently promoting its Blast X product in Germany.
Aug.31
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain's cigarette volumes declined 5.2% year over year in August 2026, according to government data cited by UBS and reported by Investing.com on October 7. British American Tobacco's volumes fell 14.5%, followed by Imperial Brands at 8.8%, Philip Morris International at 6.6% and Japan Tobacco at 4.6%. JTI was the only one of the four companies to gain cigarette market share, rising six basis points to 26.7%. In France, official customs data showed an unadjusted 3.7% decline in cigarette deliveries. Adjusting for the difference in delivery days produces a decline of approximately 8.3%, consistent with the UBS figure. The bank also estimated the earnings exposure of major tobacco companies to both markets.
Market
Oct.13
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
China's Ministry of Finance and State Taxation Administration announced on October 12, 2026, that value-added tax (VAT) export rebates for vape devices, nicotine and its salts, and certain non-combustible inhalation products will be eliminated from April 1, 2027. The measure adds four tobacco- and nicotine-related customs codes, including 8543400010, which covers vape devices and qualifying empty pods. China previously eliminated rebates for nicotine-containing vaping products and devices under code 8543400090 in April 2026. According to industry classification information held by 2Firsts, the latter currently corresponds to heated tobacco devices. Export excise tax refund and exemption arrangements will remain unchanged.
Special Report
Oct.12